|
Vascular Diseases
|
0.010 |
Biomarker
|
group |
BEFREE |
This indicates that CD34‑CD133+ cells are more pluripotent compared to the CD34+CD133+ EPC subset, which may have important consequences for the therapy of vascular diseases.
|
31746407 |
2020 |
|
Fibrosis, Liver
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Therefore, we investigated the effect of Alu-mediated p21 transcriptional regulator (APTR), fibroblast growth factor-inducible 14 (Fn14) and CD133 expressions on liver fibrosis in Indonesian BA patients.
|
31549181 |
2020 |
|
Disseminated Malignant Neoplasm
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Immunohistochemical analysis showed the strong expression of CD133 in metastatic cancer.
|
31646784 |
2020 |
|
Intermediate cell carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In HCC-INT, the CD133 positive rate in the INT component (83.3%) was significantly higher than the HCC component (8.3%) (P=0.001).
|
31661725 |
2020 |
|
Juvenile astrocytoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Clinical significance of CD133 and Nestin in astrocytic tumor: The correlation with pathological grade and survival.
|
31677196 |
2020 |
|
Adult Astrocytic Tumor
|
0.010 |
Biomarker
|
disease |
BEFREE |
Clinical significance of CD133 and Nestin in astrocytic tumor: The correlation with pathological grade and survival.
|
31677196 |
2020 |
|
Malignant Adult Brain Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
CD133 has reproducibly been shown to correlate with disease progression, recurrence, and poor overall survivorship in the malignant adult brain tumor, glioblastoma (GBM).
|
31695152 |
2020 |
|
Cirrhosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Intriguingly, CD133 expression was strongly related with the survival of BA patients (p = 0.0061), but not with age at Kasai procedure (p = 0.36) and the presence of cirrhosis (p = 0.77).
|
31549181 |
2020 |
|
Primary Myelofibrosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Genotyping of >2000 colonies from CD133+HSC and progenitors from PMF patients confirmed the complex genetic heterogeneity within the neoplastic population.
|
29907810 |
2019 |
|
Rheumatoid Arthritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
We performed flow cytometry studies in 134 consecutive asymptomatic patients with rheumatoid arthritis to derive osteogenic circulating OCN-positive (OCN+) CD34+KDR+ vs. CD34+CD133+KDR+ conventional EPC.
|
31017736 |
2019 |
|
Ascites
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Glycosylation of ascites-derived exosomal CD133: a potential prognostic biomarker in patients with advanced pancreatic cancer.
|
30805710 |
2019 |
|
Azoospermia
|
0.010 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to investigate the relationship of the CD133 and CD24 genes with spermatogenesis defects and examine them as a candidate a useful biomarker for azoospermia men.
|
31054360 |
2019 |
|
Hodgkin Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Levels of circulating CD34(+)/VEGFR2(+) and CD133(+)/VEGFR2(+) were significantly higher in the newly diagnosed untreated patients with HL compared to the patients with HL in remission (P = 0.03 and P = 0.005, respectively), in the patients in remission compared to the patients with diabetes (P = 0.011 and P < 0.001, respectively), and in the patients in remission compared to the healthy individuals (P = 0.08 and P = 0.003, respectively).
|
30549248 |
2019 |
|
Oligospermia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical analysis of CD133 revealed moderate, partial staining in the HS group, compared to substantial, wide-spread staining in the OA group.
|
31054360 |
2019 |
|
Pancreatic Neoplasm
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our study thus showed that GAS5 acts as a molecular switch for regulating quiescence and growth arrest in CD133+ population, that is responsible for aggressive biology of pancreatic tumors.
|
31740660 |
2019 |
|
Periodontitis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Moreover, there was a proportional increase in CD133+/KDR+ levels with a progressive increase in number of teeth (<i>p</i>-trend < 0.001), while there was a proportional decrease in CD133+/KDR+ levels with a proportional increase in clinical attachment level (CAL, <i>p</i>-trend = 0.003), probing depth (PD, <i>p</i>-trend = 0.007), and bleeding sites (bleeding on probing (BOP), <i>p</i>-trend < 0.001) as an extent measure of periodontitis.
|
31817862 |
2019 |
|
Prostatic Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
The CD44 <sup>(+)</sup>, CD133 <sup>(+)</sup> cell subpopulations were isolated from human prostate tumors which exhibit stem-like properties showing therapeutic-resistance, capacity of self-renewal, and exact recapitulation of the original tumor <i>in vivo</i>.
|
30728896 |
2019 |
|
Renal Artery Stenosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
CD24+/CD133+ STCs were isolated from pig kidneys after 10-weeks of RAS or sham (<i>n</i> = 3 each) and their gene cargo analyzed using high-throughput mRNAseq.
|
31614781 |
2019 |
|
Androgen-Insensitivity Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
To understand the mechanisms of augmented arteriogenesis and angiogenesis in acute ischemic stroke (AIS) patients, we investigated whether circulating stem cells (CD133+), early endothelial progenitor cells (CD133+/VEGFR2+), and endothelial cells (ECs; CD34¯/CD133¯/VEGFR2+) were increasingly mobilized during AIS, and whether there were correlations between EPC levels, growth factor levels and inflammatory parameters.
|
30706812 |
2019 |
|
Ichthyosis, X-Linked
|
0.010 |
Biomarker
|
disease |
BEFREE |
In conclusion, ALDH1, CD44, and CD133 are not likely to be useful markers of CSCs in STS.
|
30999901 |
2019 |
|
Polycystic Kidney, Autosomal Dominant
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Among these, CD133 was upregulated in exosomes from autosomal dominant polycystic kidney disease and validated by ELISA.
|
31018934 |
2019 |
|
Adult Hodgkin Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Levels of circulating CD34(+)/VEGFR2(+) and CD133(+)/VEGFR2(+) were significantly higher in the newly diagnosed untreated patients with HL compared to the patients with HL in remission (P = 0.03 and P = 0.005, respectively), in the patients in remission compared to the patients with diabetes (P = 0.011 and P < 0.001, respectively), and in the patients in remission compared to the healthy individuals (P = 0.08 and P = 0.003, respectively).
|
30549248 |
2019 |
|
Adult Soft Tissue Sarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
This study examined the expression of the putative cancer stem cell markers ALDH1, CD44, and CD133; the angiogenesis marker CD31; and the macrophage marker CD68 in soft tissue sarcomas (STS) before and after 4 cycles of chemotherapy with doxorubicin and ifosfamide in 31 patients with high-grade soft tissue sarcoma in a prospective clinical trial.
|
30999901 |
2019 |
|
Childhood Hodgkin Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Levels of circulating CD34(+)/VEGFR2(+) and CD133(+)/VEGFR2(+) were significantly higher in the newly diagnosed untreated patients with HL compared to the patients with HL in remission (P = 0.03 and P = 0.005, respectively), in the patients in remission compared to the patients with diabetes (P = 0.011 and P < 0.001, respectively), and in the patients in remission compared to the healthy individuals (P = 0.08 and P = 0.003, respectively).
|
30549248 |
2019 |
|
Childhood Soft Tissue Sarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
This study examined the expression of the putative cancer stem cell markers ALDH1, CD44, and CD133; the angiogenesis marker CD31; and the macrophage marker CD68 in soft tissue sarcomas (STS) before and after 4 cycles of chemotherapy with doxorubicin and ifosfamide in 31 patients with high-grade soft tissue sarcoma in a prospective clinical trial.
|
30999901 |
2019 |